公开(公告)号：US20230136323A1

公开(公告)日：2023-05-04

申请号：US17910629

申请日：2021-03-18

Applicant: KUNIMINE INDUSTRIES CO., LTD. ,  OSAKA UNIVERSITY

Inventor： Munehiro KUBOTA ,  Kazutake TSUJIKAWA

IPC: C12M3/00 ,  C12N5/07

Abstract: A spheroid formation promoter, including: inorganic particles having adsorbability as an active ingredient; and a method of promoting spheroid formation, including the step of: mixing a dispersion liquid of the spheroid formation promoter and a cell suspension to obtain a mixture in which the inorganic particles having adsorbability contained in the spheroid formation promoter are dispersed, and culturing a cell contained in the obtained mixture to promote spheroid formation.

公开(公告)号：US20230181628A1

公开(公告)日：2023-06-15

申请号：US17999347

申请日：2021-05-19

Applicant: OSAKA UNIVERSITY

Inventor： Kazutake TSUJIKAWA ,  Kiyoto TAKAMORI ,  Takekatsu SHIBATA

IPC: A61K33/14 ,  A61P35/00 ,  A61P13/10 ,  A61K31/14 ,  A61P15/00 ,  A61P1/00 ,  A61P1/18

CPC classification number: A61K33/14 ,  A61P35/00 ,  A61P13/10 ,  A61K31/14 ,  A61P15/00 ,  A61P1/00 ,  A61P1/18

Abstract: The present invention provides an epithelial cancer therapeutic agent with less side effects. In order to achieve the above object, an epithelial cancer therapeutic agent of the present invention includes: at least one material selected from the group consisting of oxo acid, oxo acid ion, and oxo acid salt, wherein the epithelial cancer therapeutic agent treats or prevents epithelial cancer.

公开(公告)号：US20220178932A1

公开(公告)日：2022-06-09

申请号：US17605327

申请日：2020-04-15

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH ,  OSAKA UNIVERSITY ,  TOSOH CORPORATION

Inventor： Koji UEDA ,  Naomi OHNISHI ,  Kazutake TSUJIKAWA ,  Norio NONOMURA ,  Motohide UEMURA ,  Kentaro JINGUSHI ,  Norihisa OHTAKE ,  Yasutoshi KAWAI

IPC: G01N33/574 ,  G01N33/535

Abstract: An object of the invention is to provide a method for detecting cancer in a simple and highly accurate manner, and a reagent that can be used in the method. A method for detecting cancer (excluding renal cell cancer), which comprises measuring the level of Azurocidin (AZU1) in a sample, in which it is determined that cancer is detected when a measured value exceeds a preset reference value. The cancer is preferably selected from the group consisting of stomach cancer, breast cancer, colorectal cancer, and lung cancer. A reagent containing an antibody that specifically recognizes AZU1 is used in detecting cancer (excluding renal cell cancer).